SILK Pengajuan SEC - Silk Road Medical, Inc- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

LEI	549300VL8KC0ZPDQHE14
CIK	1397702

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Silk Road Medical, Inc

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

September 27, 2024	15-12G	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-38847 SILK ROAD MEDICAL, INC. (Exact name of registrant as specified in
September 19, 2024	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 tm2424348d1ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13D with respect to the Shares of Silk Road Medical, Inc dated as of September 19, 2024 is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordan
September 19, 2024	SC 13D/A	SILK / Silk Road Medical, Inc / Magnetar Financial LLC - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* SILK ROAD MEDICAL, INC. (Name of Issuer) Common Stock, par value $.001 (Title of Class of Securities) 82710M100 (CUSIP Number of Class of Securities) David J. Snyderman Magnetar Capital LLC 1603 Orrington Ave. Evanston, Illinois 60201 (847) 905-4400 (Na
September 19, 2024	EX-99.2	LIMITED POWER OF ATTORNEY EX-99.2 3 tm2424348d1ex99-2.htm EXHIBIT 99.2 EXHIBIT 99.2 LIMITED POWER OF ATTORNEY Know all by these present, that I, David J. Snyderman, hereby make, constitute and appoint each of Michael Turro, Karl Wachter and Hayley Stein, or any of them acting individually, and with full power of substitution, as my true and lawful attorney-in-fact for the purpose of executing in my name, (a) in my personal
September 17, 2024	S-8 POS	As filed with the Securities and Exchange Commission on September 17, 2024 As filed with the Securities and Exchange Commission on September 17, 2024 Registration No.
September 17, 2024	S-8 POS	As filed with the Securities and Exchange Commission on September 17, 2024 As filed with the Securities and Exchange Commission on September 17, 2024 Registration No.
September 17, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2024 SILK ROAD MEDI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2024 SILK ROAD MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation) (Commiss
September 17, 2024	EX-3.1	AMENDED AND RESTATED CERTIFICATE OF INCORPORATION SILK ROAD MEDICAL, INC. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SILK ROAD MEDICAL, INC. 1. The name of the corporation is: Silk Road Medical, Inc. (the “Corporation”). 2. The address of the registered office of the Corporation in the State of Delaware is Corporation Service Company, 251 Little Falls Drive, Wilmington, DE, county of New Castle, 19808. The name of the registered agent of the Corpor
September 17, 2024	S-8 POS	As filed with the Securities and Exchange Commission on September 17, 2024 As filed with the Securities and Exchange Commission on September 17, 2024 Registration No.
September 17, 2024	S-8 POS	As filed with the Securities and Exchange Commission on September 17, 2024 As filed with the Securities and Exchange Commission on September 17, 2024 Registration No.
September 17, 2024	S-8 POS	As filed with the Securities and Exchange Commission on September 17, 2024 As filed with the Securities and Exchange Commission on September 17, 2024 Registration No.
September 17, 2024	POS AM	As filed with the Securities and Exchange Commission on September 17, 2024 As filed with the Securities and Exchange Commission on September 17, 2024 Registration No.
September 17, 2024	EX-3.2	SILK ROAD MEDICAL, INC. ARTICLE I Exhibit 3.2 BY-LAWS OF SILK ROAD MEDICAL, INC. ARTICLE I STOCKHOLDERS Section 1. ANNUAL MEETING. The annual meeting of the stockholders of Silk Road Medical, Inc. (the “Corporation”), for the purpose of electing directors and for the transaction of such other business as may be brought before the meeting, shall be held at the principal office of the Corporation, or at such other place within or wi
September 17, 2024	S-8 POS	As filed with the Securities and Exchange Commission on September 17, 2024 As filed with the Securities and Exchange Commission on September 17, 2024 Registration No.
September 13, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2024 SILK ROAD MEDI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2024 SILK ROAD MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation) (Commiss
September 6, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2024 SILK ROAD MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation) (Commissi
August 28, 2024	DEFR14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi
August 12, 2024	SC 13D	SILK / Silk Road Medical, Inc / Magnetar Financial LLC - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* SILK ROAD MEDICAL, INC. (Name of Issuer) Common Stock, par value $.001 (Title of Class of Securities) 82710M100 (CUSIP Number of Class of Securities) David J. Snyderman Magnetar Capital LLC 1603 Orrington Ave. Evanston, Illinois 60201 (847) 905-4400 (Nam
August 12, 2024	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 tm2421488d1ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13D with respect to the Shares of Silk Road Medical, Inc. dated as of August 12, 2024 is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance
August 12, 2024	EX-99.2	LIMITED POWER OF ATTORNEY EX-99.2 3 tm2421488d1ex99-2.htm EXHIBIT 99.2 EXHIBIT 99.2 LIMITED POWER OF ATTORNEY Know all by these present, that I, David J. Snyderman, hereby make, constitute and appoint each of Michael Turro, Karl Wachter and Hayley Stein, or any of them acting individually, and with full power of substitution, as my true and lawful attorney-in-fact for the purpose of executing in my name, (a) in my personal
August 9, 2024	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2024 SILK ROAD MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation) (Commission
August 7, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00
August 7, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 SILK ROAD MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation) (Commission
August 7, 2024	EX-99.1	Silk Road Medical Reports Second Quarter 2024 Financial Results Exhibit 99.1 Silk Road Medical Reports Second Quarter 2024 Financial Results SUNNYVALE, Calif., August 7, 2024 (GLOBE NEWSWIRE) - Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended June 30, 2024. “Our solid second quarter performance demonstrates continued TCAR adopti
July 29, 2024	DEFM14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D
July 19, 2024	EX-FILING FEES	CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) Silk Road Medical, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation Exhibit 107 CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) Silk Road Medical, Inc.
July 19, 2024	PREM14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ D
July 10, 2024	SC 13G/A	SILK / Silk Road Medical, Inc / Capital World Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Silk Road Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 82710M100 (CUSIP Number) June 28, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc
June 20, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2024 SILK ROAD MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation) (Commission ‎
June 18, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14A-101) PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14A-101) PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement ¨ Definitive Additional Materials þ Soliciting Material under § 240.
June 18, 2024	EX-99.1	Press Release Exhibit 99.1 PRESS RELEASE Silk Road Medical Announces Definitive Agreement to be Acquired by Boston Scientific Boston Scientific to acquire Silk Road Medical for $27.50 per share in cash SUNNYVALE, CA / June 18, 2024 / Silk Road Medical, Inc. (“Silk Road”) (NASDAQ:SILK), a leading minimally invasive medical device company for carotid artery procedures, announced today it has entered into a defini
June 18, 2024	EX-2.1	Agreement and Plan of Merger, dated as of June 17, 2024, by and among Boston Scientific Corporation, Seminole Merger Sub, Inc. and Silk Road Medical, Inc. Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among BOSTON SCIENTIFIC CORPORATION, SEMINOLE MERGER SUB, INC. and SILK ROAD MEDICAL, INC. Dated as of June 17, 2024 TABLE OF CONTENTS Page Article I THE MERGER Section 1.01 The Merger 2 Section 1.02 Closing 2 Section 1.03 Effective Time 2 Section 1.04 Effects of the Merger 2 Section 1.05 Certificate of Incorporation and By-Laws of the Surviving Corporation
June 18, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14A-101) PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14A-101) PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement ¨ Definitive Additional Materials þ Soliciting Material under § 240.
June 18, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14A-101) PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14A-101) PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement ¨ Definitive Additional Materials þ Soliciting Material under § 240.
June 18, 2024	EX-99.1	Silk Road Medical Announces Definitive Agreement to be Acquired by Boston Scientific Exhibit 99.1 PRESS RELEASE Silk Road Medical Announces Definitive Agreement to be Acquired by Boston Scientific Boston Scientific to acquire Silk Road Medical for $27.50 per share in cash SUNNYVALE, CA / June 18, 2024 / Silk Road Medical, Inc. (“Silk Road”) (NASDAQ:SILK), a leading minimally invasive medical device company for carotid artery procedures, announced today it has entered into a defini
June 18, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14A-101) PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14A-101) PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement ¨ Definitive Additional Materials þ Soliciting Material under § 240.
June 18, 2024	EX-2.1	Agreement and Plan of Merger, dated as of June 17, 2024, among Boston Scientific Corporation, Seminole Merger Sub, Inc. and Silk Road Medical, Inc Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among BOSTON SCIENTIFIC CORPORATION, SEMINOLE MERGER SUB, INC. and SILK ROAD MEDICAL, INC. Dated as of June 17, 2024 TABLE OF CONTENTS Page Article I THE MERGER Section 1.01 The Merger 2 Section 1.02 Closing 2 Section 1.03 Effective Time 2 Section 1.04 Effects of the Merger 2 Section 1.05 Certificate of Incorporation and By-Laws of the Surviving Corporation
June 18, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14A-101) PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14A-101) PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement ¨ Definitive Additional Materials þ Soliciting Material under § 240.
June 18, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2024 SILK ROAD MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation) (Commission F
May 30, 2024	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT SILK ROAD MEDICAL, INC. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT SILK ROAD MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation or organization) (Commission file number) (I.R.S. Employer Identification Number) 1213 Innsbruck Drive Sunnyvale, Calif
May 7, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0
April 30, 2024	EX-99.1	Silk Road Medical Reports First Quarter 2024 Financial Results Exhibit 99.1 Silk Road Medical Reports First Quarter 2024 Financial Results SUNNYVALE, Calif., April 30, 2024 (GLOBE NEWSWIRE) - Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended March 31, 2024. “Our team delivered a strong start to 2024 as we deepened relationships
April 30, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2024 SILK ROAD MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation) (Commission
April 26, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini
April 26, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State
February 29, 2024	EX-FILING FEES	Filing Fee Table (Filed herewith). Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Silk Road Medical, Inc.
February 29, 2024	S-8	As filed with the Securities and Exchange Commission on February 28, 2024 As filed with the Securities and Exchange Commission on February 28, 2024 Registration No.
February 28, 2024	EX-10.5	Silk Road Medical, Inc. 2019 Equity Incentive Plan Exhibit 10.5 SILK ROAD MEDICAL, INC. 2019 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: · to attract and retain the best available personnel for positions of substantial responsibility, · to provide additional incentive to Employees, Directors and Consultants, and · to promote the success of the Company’s business. The Plan permits the grant of Incentive Sto
February 28, 2024	EX-97.1	Silk Road Medical, Inc. Clawback Policy Exhibit 97.1 SILK ROAD MEDICAL, INC. CLAWBACK POLICY This Silk Road Medical, Inc. Clawback Policy (this “Policy”) was approved effective as of October 2, 2023 (the “Effective Date”) by the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of Silk Road Medical, Inc. (the “Company”). This Policy is adopted pursuant to and intended to comply with Rule 5608 (Recovery o
February 28, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 SILK ROAD MEDIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 SILK ROAD MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation) (Commissi
February 28, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-38847 SILK ROAD MEDICAL,
February 28, 2024	EX-10.9	Form of Employment Agreement between Silk Road Medical, Inc. and each executive officer Exhibit 10.9 EMPLOYMENT AGREEMENT INTRODUCTION: This Employment Agreement and any addenda or exhibits attached hereto (“Agreement”) is between Silk Road Medical, Inc. (“Employer”) and (“Employee”, “You,” or “Your”) (collectively the “Parties”). This Agreement, and any addenda or exhibits, describe important aspects of, and obligations regarding, Your employment with Employer, including the ownersh
February 28, 2024	EX-99.1	Silk Road Medical Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Financial Outlook Exhibit 99.1 Silk Road Medical Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Financial Outlook SUNNYVALE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) - Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months and full year ended December 31, 2023. “With
February 28, 2024	EX-10.1	Form of Indemnification Agreement between Silk Road Medical, Inc. and each non-employee director and executive officer Exhibit 10.1 SILK ROAD MEDICAL, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is dated as of , and is between Silk Road Medical, Inc., a Delaware corporation (together with its affiliates and subsidiaries, the “Company”), and (“Indemnitee”). RECITALS A.Indemnitee’s service to the Company substantially benefits the Company. B.Individuals are reluctant to serve as
February 28, 2024	EX-10.6	Form of Silk Road Medical, Inc. 2019 Equity Incentive Plan Stock Option Agreement Exhibit 10.6 SILK ROAD MEDICAL, INC. 2019 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT Unless otherwise defined herein, the terms defined in the Silk Road Medical, Inc. 2019 Equity Incentive Plan (the “Plan”) will have the same defined meanings in this Stock Option Agreement, which includes the Notice of Stock Option Grant (the “Notice of Grant”), the Terms and Conditions of Stock Option Grant
February 28, 2024	EX-3.1	Restated Certificate of Incorporation of Silk Road Medical, Inc. Exhibit 3.1 Delaware Page 1 The First State I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE RESTATED CERTIFICATE OF “SILK ROAD MEDICAL, INC.”, FILED IN THIS OFFICE ON THE EIGHTH DAY OF DECEMBER, A.D. 2023, AT 2:20 O`CLOCK P.M. 4319923 8100 Authentication: 20477
February 28, 2024	EX-10.36	First Amendment to Lease dated as of August 27, 2018 between Hanover Properties Ltd. and Silk Road Medical, Inc. Exhibit 10.36 FIRST AMENDMENT TO LEASE This First Amendment to Lease, dated as of August 27, 2018, is entered into by and between Hanover Properties, Ltd., a California limited partnership (“Landlord”), and Silk Road Medical, Inc., a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant entered into that certain Lease Agreement dated as of November 30, 2017 (the “Lease”) for those c
February 28, 2024	EX-4.3	Description of Silk Road Medical, Inc. securities registered pursuant to Section 12 of the Securities Exchange Act of 1934 Exhibit 4.3 DESCRIPTION OF SILK ROAD MEDICAL, INC. SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 General Silk Road Medical, Inc., a Delaware corporation (Silk Road Medical, we, us, and our), has only one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (Exchange Act): common stock, par value $0.001 per share (c
February 13, 2024	SC 13G/A	SILK / Silk Road Medical, Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01921-silkroadmedicalinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Silk Road Medical Inc Title of Class of Securities: Common Stock CUSIP Number: 82710M100 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to des
January 9, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2024 SILK ROAD MEDICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2024 SILK ROAD MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation) (Commission
January 9, 2024	EX-99.1	SILKROAD MEDICAl J.P. Morgan Healthcare Conference January 2024 Image: Donna, TCAR® and CEA patient Forward Looking Statement Certain information contained in this presentation and statements made orally during this presentation relate to or are base Exhibit 99.1 SILKROAD MEDICAl J.P. Morgan Healthcare Conference January 2024 Image: Donna, TCAR® and CEA patient Forward Looking Statement Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and Silk Road’s own internal estimates and researc
November 8, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 SILK ROAD MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation) (Commissio
November 8, 2023	EX-99.1	Silk Road Medical Reports Third Quarter 2023 Financial Results Exhibit 99.1 Silk Road Medical Reports Third Quarter 2023 Financial Results SUNNYVALE, Calif., November 8, 2023 (GLOBE NEWSWIRE) - Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended September 30, 2023. “As announced on November 2, we are thrilled to welcome Chas McKha
November 8, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe
November 2, 2023	EX-10.4	Indemnification Agreement dated as of November 2, 2023 between Silk Road Medical, Inc. and Charles McKhann (filed herewith) Exhibit 10.4 SILK ROAD MEDICAL, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is dated as of November 2, 2023, and is between Silk Road Medical, Inc., a Delaware corporation (together with its affiliates and subsidiaries, the “Company”), and Charles McKhann (“Indemnitee”). RECITALS A.Indemnitee’s service to the Company substantially benefits the Company. B.Indivi
November 2, 2023	EX-10.1	Employment Offer Letter Agreement dated October 30, 2023 between Silk Road Medical, Inc. and Charles McKhann Exhibit 10.1 October 30, 2023 Charles McKhann [*] [*] Dear Chas, On behalf of Silk Road Medical, Inc. (the “Company” or “Silk Road Medical”), I am pleased to offer you employment in the position of Chief Executive Officer and as a member of our Board of Directors. This letter agreement sets forth the terms and conditions of your employment with the Company from and after the date o
November 2, 2023	EX-10.7	Executive Retirement and Transition Agreement dated as of November 2, 2023 between Silk Road Medical, Inc. and Erica J. Rogers (filed herewith) Exhibit 10.7 EXECUTIVE RETIREMENT AND TRANSITION AGREEMENT This Executive Retirement and Transition Agreement (this “Agreement”), together with the Release of Claims (“Release”) attached as Exhibit A to this Agreement, are made by and between Erica J. Rogers, a California resident, on behalf of herself, her agents, heirs, executors and administrators (the “Executive”), and Silk Road Medical, Inc.,
November 2, 2023	EX-10.8	Consulting Agreement dated as of November 2, 2023 between Silk Road Medical, Inc. and Erica J. Rogers (filed herewith) Exhibit 10.8 SILK ROAD MEDICAL, INC. CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”) is made and entered into as of November 2, 2023 by and between Silk Road Medical, Inc., a Delaware corporation (the “Company”), and Erica J. Rogers (the “Consultant”), a California resident. The Company desires to retain the Consultant as an independent contractor to perform consulting services
November 2, 2023	EX-10.2	Employment Agreement dated November 2, 2023 between Silk Road Medical, Inc. and Charles McKhann (filed herewith) Exhibit 10.2 EMPLOYMENT AGREEMENT INTRODUCTION: This Employment Agreement and any addenda or exhibits attached hereto (“Agreement”) is between Silk Road Medical, Inc. (“Employer”) and Charles McKhann (“Employee”, “You,” or “Your”) (collectively the “Parties”). This Agreement, and any addenda or exhibits, describe important aspects of, and obligations regarding, Your employment with Employer, inclu
November 2, 2023	EX-10.3	Change in Control and Severance Agreement effective as of November 2, 2023 between Silk Road Medical, Inc. and Charles McKhann Exhibit 10.3 SILK ROAD MEDICAL, INC CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (this “Agreement”) is made between Silk Road Medical, Inc. (the “Company”) and Charles McKhann (the “Executive”), effective as of November 2, 2023 (the “Effective Date”). This Agreement provides certain protections to the Executive in connection with a change in control of t
November 2, 2023	EX-10.5	Form of Silk Road Medical, Inc. 2019 Equity Incentive Plan Restricted Stock Unit Agreement Exhibit 10.5 SILK ROAD MEDICAL, INC. 2019 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT NOTICE OF RESTRICTED STOCK UNIT GRANT Unless otherwise defined herein, the terms defined in the Silk Road Medical, Inc. 2019 Equity Incentive Plan (the “Plan”) will have the same defined meanings in this Restricted Stock Unit Agreement, which includes the Notice of Restricted Stock Unit Grant (the “Noti
November 2, 2023	EX-99.1	Silk Road Medical Names Chas McKhann Chief Executive Officer Accomplished Leader with Over 25 Years of Medical Device Industry Experience Exhibit 99.1 Silk Road Medical Names Chas McKhann Chief Executive Officer Accomplished Leader with Over 25 Years of Medical Device Industry Experience SUNNYVALE, Calif. – November 2, 2023 – Silk Road Medical, Inc. (Nasdaq: SILK) (“Silk Road” or the “Company”), a company focused on reducing the risk of stroke and its devastating impact, today announced that Chas McKhann has been appointed C
November 2, 2023	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 SILK ROAD MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation) (Commissio
October 20, 2023	SC 13G	SILK / Silk Road Medical Inc / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.
October 10, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2023 SILK ROAD MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation) (Commissio
October 10, 2023	EX-99.1	Silk Road Medical Announces Preliminary Third Quarter 2023 Revenue and Provides Revised 2023 Outlook Exhibit 99.1 Silk Road Medical Announces Preliminary Third Quarter 2023 Revenue and Provides Revised 2023 Outlook SUNNYVALE, Calif. – October 10, 2023 – Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced preliminary revenue for the quarter ended September 30, 2023, and provided an update to full year 2023 revenue
October 10, 2023	EX-99.2	Silk Road Medical Announces Retirement of CEO Erica Rogers Working with Leading Executive Search Firm to Identify Successor Exhibit 99.2 Silk Road Medical Announces Retirement of CEO Erica Rogers Working with Leading Executive Search Firm to Identify Successor SUNNYVALE, Calif. – October 10, 2023 – Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that CEO Erica Rogers plans to retire from the Company following the completion of a
September 15, 2023	EX-10.1	Letter Agreement dated as of September 15, 2023 between Silk Road Medical, Inc. and Andrew S. Davis Exhibit 10.1 1213 Innsbruck Drive, Sunnyvale, C A 94089 WWW.SILKROADMED.COM September 15, 2023 Andrew Davis Letter Agreement Regarding Supplemental Compensation Package Dear Andy, I am pleased to confirm that the Compensation Committee of the Board of Directors of Silk Road Medical (“the Company”) has authorized me to offer you a supplemental compensation package pursuant and subje
September 15, 2023	EX-10.2	Amended and Restated Employment Agreement dated as of September 15, 2023 between Silk Road Medical, Inc. and Andrew S. Davis Exhibit 10.2 AMENDED AND RESTATED EMPLOYMENT AGREEMENT INTRODUCTION: This Employment Agreement and any addenda or exhibits attached hereto (“Agreement”) is between Silk Road Medical, Inc. (“Employer”) and Andrew Davis (“Employee”, “You,” or “Your”) (collectively the “Parties”). This Agreement, and any addenda or exhibits, describe important aspects of, and obligations regarding, Your employment wi
September 15, 2023	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2023 SILK ROAD MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation) (Commiss
August 10, 2023	SC 13G/A	SILK / Silk Road Medical Inc / ALLIANCEBERNSTEIN L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Silk Road Medical Inc (Name of Issuer) Common Stock (Title of Class of Securities) 82710M100 (CUSIP Number) July 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche
August 8, 2023	EX-10.4	Amended and Restated Change in Control and Severance Agreement effective as of June 22, 2022 between Silk Road Medical, Inc. and Erica Rogers Exhibit 10.4 SILK ROAD MEDICAL, Inc. AMENDED AND RESTATED CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Amended and Restated Change in Control and Severance Agreement (the “Agreement”) is made between Silk Road Medical, Inc. (the “Company”) and Erica Rogers (the “Executive”), effective as of June 22, 2022. This Agreement amends and restates that certain Change in Control and Severance Agreement e
August 8, 2023	EX-10.5	Amended and Restated Change in Control and Severance Agreement effective as of June 22, 2022 between Silk Road Medical, Inc. and Lucas Buchanan Exhibit 10.5 SILK ROAD MEDICAL, Inc. AMENDED AND RESTATED CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Amended and Restated Change in Control and Severance Agreement (the “Agreement”) is made between Silk Road Medical, Inc. (the “Company”) and Lucas Buchanan (the “Executive”), effective as of June 22, 2022. This Agreement amends and restates that certain Change in Control and Severance Agreement
August 8, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00
August 8, 2023	EX-10.6	Amended and Restated Change in Control and Severance Agreement effective as of June 22, 2022 between Silk Road Medical, Inc. and Andrew Davis Exhibit 10.6 SILK ROAD MEDICAL, Inc. AMENDED AND RESTATED CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Amended and Restated Change in Control and Severance Agreement (the “Agreement”) is made between Silk Road Medical, Inc. (the “Company”) and Andrew Davis (the “Executive”), effective as of June 22, 2022. This Agreement amends and restates that certain Change in Control and Severance Agreement e
August 1, 2023	EX-99.1	Silk Road Medical Reports Second Quarter 2023 Financial Results Exhibit 99.1 Silk Road Medical Reports Second Quarter 2023 Financial Results SUNNYVALE, Calif., August 1, 2023 (GLOBE NEWSWIRE) - Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended June 30, 2023. “Silk Road is the leading force in stroke prevention for patients with s
August 1, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2023 SILK ROAD MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation) (Commission
June 23, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 SILK ROAD MEDICAL, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 SILK ROAD MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation) (Commission ‎
June 23, 2023	EX-3.1	Certificate of Amendment to Amended and Restated Certificate of Incorporation of Silk Road Medical, Inc. Delaware The First State Page 1 I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF “SILK ROAD MEDICAL, INC.”, FILED IN THIS OFFICE ON THE TWENTY-FIRST DAY OF JUNE, A.D. 2023, AT 6:34 O`CLOCK P.M. 4319923 8100 Authentication: 2035987
May 30, 2023	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT SILK ROAD MEDICAL, INC. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT SILK ROAD MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation or organization) (Commission file number) (I.R.S. Employer Identification Number) 1213 Innsbruck Drive Sunnyvale, Calif
May 15, 2023	EX-4.3	Form of Indenture Exhibit 4.3 SILK ROAD MEDICAL, INC. INDENTURE Dated as of, 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 5 Section 1.4 Rules of Construction 5 ARTICLE II THE SECURITIES 5 Section 2.1 Issuable in Series 5 Se
May 15, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Silk Road Medical, Inc.
May 15, 2023	S-3ASR	As filed with the Securities and Exchange Commission on May 15, 2023 As filed with the Securities and Exchange Commission on May 15, 2023 Registration No.
May 12, 2023	RW	May 12, 2023 May 12, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re:Silk Road Medical, Inc. Request to Withdraw Registration Statement on Form S-3 filed May 9, 2023 (File No. 333-271779) Ladies and Gentlemen: Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended, or the Securities Act, Silk Road Medic
May 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 00
May 9, 2023	EX-10.4	Fifth Amendment to Supply Agreement dated as of May 8, 2023 between Cordis US Corp., as successor to Cordis Corporation, and Silk Road Medical, Inc Exhibit 10.4 [PORTIONS HEREIN IDENTIFIED BY [***] HAVE BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE EXCLUDED INFORMATION IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.] Fifth Amendment To Supply Agreement This Fifth Amendment To Supply Agreement (this “Fifth Amendment”) is entered into as of the 8th day of May, 2023 (the “Fifth Amendment Eff
May 9, 2023	EX-99.1	Silk Road Medical Reports First Quarter 2023 Financial Results Exhibit 99.1 Silk Road Medical Reports First Quarter 2023 Financial Results SUNNYVALE, Calif., May 9, 2023 (GLOBE NEWSWIRE) - Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended March 31, 2023. “2023 is off to a strong start as we execute against our U.S. commercial op
May 9, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Silk Road Medical, Inc.
May 9, 2023	EX-10.3	First Amendment to License Agreement dated as of May 8, 2023 between Cordis US Corp., as successor to Cordis Corporation, and Silk Road Medical, Inc Exhibit 10.3 [PORTIONS HEREIN IDENTIFIED BY [***] HAVE BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE EXCLUDED INFORMATION IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.] First Amendment To License Agreement This First Amendment To License Agreement (this “First Amendment”) is entered into as of the 8th day of May, 2023 (the “First Amendment E
May 9, 2023	EX-10.2	Second Amendment to Lease dated as of May 3, 2023 between Hanover Properties Ltd. and Silk Road Medical, Inc. Exhibit 10.2 SECOND AMENDMENT TO LEASE This Second Amendment to Lease (“Second Amendment”), dated as of May 3, 2023, is entered into by and between Hanover Properties, Ltd., a California limited partnership (“Landlord”), and Silk Road Medical, Inc., a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant entered into that Lease Agreement dated as of November 30, 2017 (“Original Lease”
May 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 SILK ROAD MEDICAL, IN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 SILK ROAD MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation) (Commission ‎Fi
May 9, 2023	EX-4.3	Form of Indenture EX-4.3 2 silk-20230509xex43.htm EX-4.3 Exhibit 4.3 SILK ROAD MEDICAL, INC. INDENTURE Dated as of, 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 5 Section 1.4 Rules of Construction 5 ARTICLE II THE SECURITIES 5
May 9, 2023	S-3	As filed with the Securities and Exchange Commission on May 9, 2023 As filed with the Securities and Exchange Commission on May 9, 2023 Registration No.
May 9, 2023	EX-10.1	Form of Performance Stock Unit Agreement under the Silk Road Medical, Inc. 2019 Equity Incentive Plan Exhibit 10.1 SILK ROAD MEDICAL, INC. 2019 EQUITY INCENTIVE PLAN FORM OF PERFORMANCE STOCK UNIT AGREEMENT NOTICE OF PERFORMANCE STOCK UNIT GRANT Unless otherwise defined herein, the terms defined in the Silk Road Medical, Inc. 2019 Equity Incentive Plan (the “Plan”) will have the same defined meanings in this Performance Stock Unit Agreement, which includes the Notice of Performance Stock Unit Gran
April 28, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini
April 28, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State
April 14, 2023	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State
March 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2023 SILK ROAD MEDICAL, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2023 SILK ROAD MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation) (Commission ‎
March 15, 2023	EX-3.1	Amended and Restated Bylaws of Silk Road Medical, Inc Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF SILK ROAD MEDICAL, INC. (Effective as of March 15, 2023) 1 TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES 2 2.5 NOTICE OF STOCKHOLDE
February 28, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 28, 2023 SILK ROAD MEDIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 28, 2023 SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of ‎incorporation or organi
February 28, 2023	EX-10.22	Change in Control and Severance Agreement between the registrant and Kevin Klemz, dated as of June 29, 2022 Exhibit 10.22 SILK ROAD MEDICAL, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (as amended, the “Agreement”) is made between Silk Road Medical, Inc. (the “Company”) and Kevin Klemz (the “Executive”), effective as of August 15, 2022, or the Commencement Date of Employment, whichever is later (the “Effective Date”). This Agreement provides certain
February 28, 2023	EX-99.1	Silk Road Medical Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Outlook Exhibit 99.1 Silk Road Medical Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Outlook SUNNYVALE, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) - Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months and full year ended December 31, 2022. “Our
February 28, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Silk Road Medical, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stoc
February 28, 2023	S-8	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S‑8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) As filed with the Securities and Exchange Commission on February 28, 2023 Registration No.
February 28, 2023	EX-4.3	Exhibit 4.3 Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 General The following is a description of the material terms and provisions relating to our securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended, or the Exchange Act. The following description is a summary that is not compl
February 28, 2023	EX-10.17	Confirmatory Employment Letter between the registrant and Kevin Klemz, dated as of June 29, 2022 Exhibit 10.17 CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS NOT MATERIAL AND (I) WOULD BE COMPETITIVELY HARMFUL TO THE REGISTRANT IF PUBLICLY DISCLOSED OR (II) IS INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SUCH INFORMATION HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS HAVE BEEN MADE. June 29, 2022 Kevin Klemz [xxx] Delive
February 28, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-38847 S
February 28, 2023	EX-10.5	2019 Equity Incentive Plan and related form agreements Exhibit 10.5 SILK ROAD MEDICAL, INC. 2019 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: · to attract and retain the best available personnel for positions of substantial responsibility, · to provide additional incentive to Employees, Directors and Consultants, and · to promote the success of the Company’s business. The Plan permits the grant of Incentive Sto
February 14, 2023	SC 13G/A	SILK / Silk Road Medical Inc / ALLIANCEBERNSTEIN L.P. - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Silk Road Medical Inc (Name of Issuer) Common Stock (Title of Class of Securities) 82710M100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this
February 13, 2023	SC 13G/A	SILK / Silk Road Medical Inc / Capital World Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Silk Road Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 82710M100 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi
February 10, 2023	SC 13G/A	SILK / Silk Road Medical Inc / Flynn James E Passive Investment SC 13G/A 1 e618252sc13ga-silkroad.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1) * Silk Road Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 8271
February 9, 2023	SC 13G/A	SILK / Silk Road Medical Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01892-silkroadmedicalinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Silk Road Medical Inc. Title of Class of Securities: Common Stock CUSIP Number: 82710M100 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to de
November 9, 2022	EX-10.1	Second Amendment to Lease Agreement, dated September 15, 2022, by and between the Registrant and Parkers Lake Medtech LLC Exhibit 10.1 SECOND AMENDMENT TO LEASE AGREEMENT This SECOND AMENDMENT TO LEASE AGREEMENT (?Amendment?) is made and entered into this 15th day of September, 2022 (the ?Effective Date?), by and between PARKERS LAKE MEDTECH LLC, a Minnesota limited liability company (?Landlord?), and SILK ROAD MEDICAL, INC., a Delaware corporation (?Tenant?). RECITALS A. Landlord and Tenant entered into that certain
November 9, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q REGISTRATION STATEMENT The Securities Act of 1933 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q REGISTRATION STATEMENT Under The Securities Act of 1933 (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
November 8, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 8, 2022 SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of ?incorporation or organiz
November 8, 2022	EX-99.1	Silk Road Medical Reports Third Quarter 2022 Financial Results Exhibit 99.1 ? Silk Road Medical Reports Third Quarter 2022 Financial Results ? SUNNYVALE, Calif., November 8, 2022 (GLOBE NEWSWIRE) - Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended September 30, 2022. ? ?Our performance in the third quarter reflects broad-based U.S. TC
October 21, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 18, 2022 SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of ?incorporation or organiz
October 21, 2022	EX-1.1	Underwriting Agreement, dated October 18, 2022, by and among Silk Road Medical, Inc. and J.P. Morgan Securities LLC and BofA Securities, Inc., as representatives of the several underwriters named therein EX-1.1 2 silk-20221018xex11.htm EX-1.1 Exhibit 1.1 UNDERWRITING AGREEMENT SILK ROAD MEDICAL, INC. 2,325,582 Shares of Common Stock Underwriting Agreement October 18, 2022 J.P. Morgan Securities LLC BofA Securities, Inc. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o BofA Securities, Inc
October 20, 2022	EX-99.1	Silk Road Medical Announces Certain Preliminary Financial Data For Quarter Ended September 30, 2022 ? Silk Road Medical Announces Certain Preliminary Financial Data For Quarter Ended September 30, 2022 ? SUNNYVALE, Calif.
October 20, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 17, 2022 SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of ?incorporation or organiz
October 20, 2022	EX-FILING FEES	Calculation of Filing Fee Tables FORM 424(b)(5) (Form Type) Silk Road Medical, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Exhibit 107 Calculation of Filing Fee Tables FORM 424(b)(5) (Form Type) Silk Road Medical, Inc.
October 20, 2022	424B5	Prospectus Supplement (To Prospectus dated May 5, 2020) Filed Pursuant to Rule 424(b)(5) Registration No. 333-238007 ? Prospectus Supplement (To Prospectus dated May 5, 2020) ? 2,325,582 Shares Common Stock We are offering 2,325,582 shares of our common stock. Our common stock is listed on The Nasdaq Global Select Market under the symbol ?SILK.? On October 17, 2022, the last reported sale price of shares of our common stock on The Nasdaq Global Select
October 18, 2022	424B5	Subject to completion, Preliminary Prospectus Supplement dated October 17, 2022 Filed Pursuant to Rule 424(b)(5) Registration No. 333-238007 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to these securities has become effective under the Securities Act of 1933, as amended. This preliminary prospectus supplement and the accompanying prospectus are not an offer to s
October 18, 2022	FWP	Free Writing Prospectus Filed pursuant to Rule 433 and Rule 163 of the Securities Act of 1933, as amended Registration Statement No.
August 9, 2022	EX-10.17	First Amendment to Loan and Security Agreement, dated June 13, 2022, by and between the registrant and Oxford Finance, LLC EXHIBIT 10.17 ? FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT ? This First Amendment to Loan and Security Agreement (this ?Amendment?) is entered into as of June 13, 2022 and is effective as of May 27, 2022, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (?Oxford?), as collateral agent (
August 9, 2022	EX-10.18	First Amendment to Lease Agreement, dated June 30, 2022, by and between the Registrant and Parkers Lake Medtech LLC Exhibit 10.18 FIRST AMENDMENT TO LEASE AGREEMENT This FIRST AMENDMENT TO LEASE AGREEMENT (?Amendment?) is made and entered into this 30th day of June, 2022, by and between PARKERS LAKE MEDTECH LLC, a Minnesota limited liability company (?Landlord?), and SILK ROAD MEDICAL, INC., a Delaware corporation (?Tenant?). RECITALS A. Landlord and Tenant entered into that certain Lease Agreement dated as of
August 9, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q REGISTRATION STATEMENT The Securities Act of 1933 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q REGISTRATION STATEMENT Under The Securities Act of 1933 (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For
July 26, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 26, 2022 SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of ?incorporation or organizati
July 26, 2022	EX-99.1	Silk Road Medical Reports Second Quarter 2022 Financial Results ? Silk Road Medical Reports Second Quarter 2022 Financial Results ? SUNNYVALE, Calif.
June 10, 2022	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 9, 2022 SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of ?incorporation or organizatio
May 31, 2022	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 27, 2022 SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of ?incorporation or organizatio
May 31, 2022	EX-10.1	Loan and Security Agreement, dated May 27, 2022, by and between the registrant and Oxford Finance, LLC Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS NOT MATERIAL AND (I) WOULD BE COMPETITIVELY HARMFUL TO THE REGISTRANT IF PUBLICLY DISCLOSED OR (II) IS INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SUCH INFORMATION HAS BEEN MARKED WITH ?[***]? TO INDICATE WHERE OMISSIONS HAVE BEEN MADE. ? LOAN AND SECURITY AGREEMENT THIS LOAN AND SE
May 31, 2022	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) ? ? ? ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) ? Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification Number) ? 1213 Innsbruck Drive Sunnyvale, Calif
May 10, 2022	EX-10.13	Second Amendment to Loan and Security Agreement, dated April 21, 2022, by and between the registrant and Stifel Bank Exhibit 10.13 CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS NOT MATERIAL AND (I) WOULD BE COMPETITIVELY HARMFUL TO THE REGISTRANT IF PUBLICLY DISCLOSED OR (II) IS INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SUCH INFORMATION HAS BEEN MARKED WITH ?[***]? TO INDICATE WHERE OMISSIONS HAVE BEEN MADE. ? SECOND AMENDMENT TO LOAN AND SECURITY AGREE
May 10, 2022	EX-10.14	IP License Agreement, dated May 12, 2016, by and between the registrant and Route 92 Medical, Inc Exhibit 10.14 ? CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS NOT MATERIAL AND (I) WOULD BE COMPETITIVELY HARMFUL TO THE REGISTRANT IF PUBLICLY DISCLOSED OR (II) IS INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SUCH INFORMATION HAS BEEN MARKED WITH ?[***]? TO INDICATE WHERE OMISSIONS HAVE BEEN MADE. ? IP LICENSE AGREEMENT This IP License Agre
May 10, 2022	EX-10.15	IP Assignment and License Agreement, dated May 12, 2016, by and between the registrant and Route 92 Medical, Inc Exhibit 10.15 ? CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS NOT MATERIAL AND (I) WOULD BE COMPETITIVELY HARMFUL TO THE REGISTRANT IF PUBLICLY DISCLOSED OR (II) IS INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SUCH INFORMATION HAS BEEN MARKED WITH ?[***]? TO INDICATE WHERE OMISSIONS HAVE BEEN MADE. ? IP ASSIGNMENT AND LICENSE AGREEMENT This
May 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q REGISTRATION STATEMENT The Securities Act of 1933 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q REGISTRATION STATEMENT Under The Securities Act of 1933 (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For
May 4, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 4, 2022 SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of ?incorporation or organization
May 4, 2022	EX-99.1	Silk Road Medical Reports First Quarter 2022 Financial Results ? Silk Road Medical Reports First Quarter 2022 Financial Results ? SUNNYVALE, Calif.
April 29, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 ? ? ? ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? ? Check the appropriate box: ? ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defini
April 29, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 ? ? ? ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? ? Check the appropriate box: ? ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defini
April 11, 2022	SC 13G/A	SILK / Silk Road Medical Inc / ALLIANCEBERNSTEIN L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Silk Road Medical Inc (Name of Issuer) Common Stock (Title of Class of Securities) 82710M100 (CUSIP Number) March 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch
March 1, 2022	EX-4.5	Description of the registrant’s securities registered pursuant to Section 12 of the Securities Exchange Act of 1934 EX-4.5 2 silk-20211231xex45.htm EX-4.5 Exhibit 4.5 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Silk Road Medical, Inc. (the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, par value $0.001 per share. As used in this summary, the terms
March 1, 2022	S-8	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S‑8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) As filed with the Securities and Exchange Commission on March 1, 2022 Registration No.
March 1, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Silk Road Medical, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities ? ? Security Type Security Class Title Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stoc
March 1, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-38847 S
February 24, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 24, 2022 SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of ?incorporation or organi
February 24, 2022	EX-99.1	Silk Road Medical Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Financial Outlook ? Silk Road Medical Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Financial Outlook ? SUNNYVALE, Calif.
February 14, 2022	SC 13G/A	SILK / Silk Road Medical Inc / ALLIANCEBERNSTEIN L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Silk Road Medical Inc (Name of Issuer) Common Stock (Title of Class of Securities) 82710M100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this
February 11, 2022	SC 13G/A	SILK / Silk Road Medical Inc / Capital World Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Silk Road Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 82710M100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi
February 10, 2022	SC 13G/A	SILK / Silk Road Medical Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Silk Road Medical Inc. Title of Class of Securities: Common Stock CUSIP Number: 82710M100 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed
January 24, 2022	SC 13G	SILK / Silk Road Medical Inc / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.
November 9, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q REGISTRATION STATEMENT The Securities Act of 1933 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q REGISTRATION STATEMENT Under The Securities Act of 1933 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
November 9, 2021	EX-99.1	Silk Road Medical Reports Third Quarter 2021 Financial Results ? Silk Road Medical Reports Third Quarter 2021 Financial Results ? SUNNYVALE, Calif.
November 9, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 9, 2021 SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of ‎incorporation or organiz
September 13, 2021	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 13, 2021 SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of ‎incorporation or organ
August 6, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q REGISTRATION STATEMENT The Securities Act of 1933 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q REGISTRATION STATEMENT Under The Securities Act of 1933 (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For
August 6, 2021	EX-10.23	Lease Agreement by and between the registrant and ARHC UHPTHMN01 LLC, dated May 12, 2021 Exhibit 10.23 ? ? ? ? ? ? ? ? LEASE AGREEMENT ? Between ? ARHC UHPTHMN01 LLC, as Landlord And SILK ROAD MEDICAL, INC., as Tenant ? Property: ? Plymouth West Business Center Plymouth, Minnesota TABLE OF CONTENTS (Continued) Page ?Section 1 ? Summary; Premises, Term1 1.1 ?Summary of Terms1 1.2 ?Premises1 1.3 ?Project, Building, Common Areas2 1.4 ?Term3 1.5 ?Use; Compliance; Operation3 1.6 ?Options t
July 29, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 29, 2021 SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of ?incorporation or organizati
July 29, 2021	EX-99.1	Silk Road Medical Reports Second Quarter 2021 Financial Results ? Silk Road Medical Reports Second Quarter 2021 Financial Results ? SUNNYVALE, Calif.
July 26, 2021	EX-99.1	Silk Road Medical Names Dr. Tanisha Carino to Board of Directors ? Silk Road Medical Names Dr. Tanisha Carino to Board of Directors ? SUNNYVALE, Calif. ? July 22, 2021 ? Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that it has appointed Dr. Tanisha Carino to its Board of Directors. ? Tanisha Carino, Ph.D., is a health policy expert bringing over 20 years of experience drivin
July 26, 2021	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 22, 2021 SILK ROAD MEDICAL, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 22, 2021 SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of ‎incorporation or organizati
June 22, 2021	EX-3.1	Certificate of Amendment of Amended and Restated Certificate of Incorporation Exhibit 3.1 ? Certificate of Amendment to THE Amended and Restated Certificate of Incorporation of SILK ROAD MEDICAL, Inc. ? ? Silk Road Medical, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), hereby certifies as follows: ? FIRST: The name of the Corporation is Silk Road Medical, Inc., and the original Certificate of Incorporation of this Co
June 22, 2021	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 17, 2021 SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of ?incorporation or organizati
June 10, 2021	SC 13G/A	SILK / Silk Road Medical Inc / Capital World Investors - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Silk Road Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 82710M100 (CUSIP Number) May 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to
May 18, 2021	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2021 SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of ?incorporation or organizatio
May 10, 2021	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q REGISTRATION STATEMENT Under The Securities Act of 1933 (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For
May 10, 2021	EX-10.22	First Amendment to Loan and Security Agreement, dated January 15, 2021, by and between the registrant and Stifel Bank. EX-10.22 2 silk-20210331xex1022.htm EX-10.22 Exhibit 10.22 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT This First Amendment to Loan and Security Agreement (this “Amendment”) is entered into as of January 15, 2021, by and between STIFEL BANK (“Bank”) and SILK ROAD MEDICAL, INC., a Delaware corporation (“Borrower”). RECITALS Borrower and Bank are parties to that certain Loan and Security Ag
May 4, 2021	EX-99.1	Silk Road Medical Reports First Quarter 2021 Financial Results ? Silk Road Medical Reports First Quarter 2021 Financial Results ? SUNNYVALE, Calif.
May 4, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 4, 2021 SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of ?incorporation or organization
April 26, 2021	DEF 14A	- DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State
March 18, 2021	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): MARCH 16, 2021 SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation or organizati
March 1, 2021	EX-99.1	Silk Road Medical Reports Fourth Quarter and Full Year 2020 Financial Results Submitted PMA Supplement for ENROUTE Stent in Standard Surgical Risk Patients Silk Road Medical Reports Fourth Quarter and Full Year 2020 Financial Results Submitted PMA Supplement for ENROUTE Stent in Standard Surgical Risk Patients SUNNYVALE, Calif.
March 1, 2021	S-8	- S-8 As filed with the Securities and Exchange Commission on March 1, 2021 Registration No.
March 1, 2021	EX-4.5	Description of the registrant’s securities registered pursuant to Section 12 of the Securities Exchange Act of 1934 Exhibit 4.5 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Silk Road Medical, Inc. (the ?Company?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, par value $0.001 per share. As used in this summary, the terms ?Silk Road Medical,? ?the Company,? ?we,? ?
March 1, 2021	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 . OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38847 SILK ROAD ME
March 1, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 1, 2021 SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation or organizatio
February 16, 2021	SC 13G	SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Silk Road Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 82710M100 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this
February 11, 2021	SC 13G/A	SCHEDULE 13G SIGNATURE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) SILK RD MED INC (Name of Issuer) COM (Title of Class of Securities) 82710M100 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed
February 10, 2021	SC 13G	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Silk Road Medical Inc. Title of Class of Securities: Common Stock CUSIP Number: 82710M100 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐
February 8, 2021	SC 13G	SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Silk Road Medical Inc (Name of Issuer) Common Stock (Title of Class of Securities) 82710M100 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc
February 4, 2021	8-K	Regulation FD Disclosure - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): FEBRUARY 4, 2021 SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation or organiza
January 25, 2021	8-K	Regulation FD Disclosure - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): JANUARY 25, 2021 SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation or organiza
January 13, 2021	8-K	Regulation FD Disclosure - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 13, 2021 SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation or organiza
January 12, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 12, 2021 SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation or organiza
January 12, 2021	EX-99.1	of Silk Road Medical, Inc. dated silkpresentationjpmjan20
December 3, 2020	EX-99.1	Silk Road Medical Announces Changes to Board of Directors Silk Road Medical Announces Changes to Board of Directors SUNNYVALE, Calif. – December 3, 2020 – Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the appointment of Kevin Ballinger to the company’s Board of Directors. Simultaneously, the company also announced the resignation of current board member, Ruoxi Chen. Bo
December 3, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 3, 2020 SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation or organiza
November 16, 2020	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q REGISTRATION STATEMENT The Securities Act of 1933 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q REGISTRATION STATEMENT Under The Securities Act of 1933 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition pe
November 10, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 10, 2020 SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation or organiz
November 10, 2020	EX-99.1	Silk Road Medical Reports Third Quarter 2020 Financial Results Silk Road Medical Reports Third Quarter 2020 Financial Results SUNNYVALE, Calif. – November 10, 2020 – Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended September 30, 2020. “We had a strong third quarter in which our revenues grew 18% year over year. Our patient first cult
November 4, 2020	EX-9.01	Loan and Security Agreement, dated October 29, 2020, by and between the registrant and Stifel Bank EX-9.01 2 silkroad-8xkaexredactedloa.htm EX-9.01 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. SILK ROAD MEDICAL, INC. STIFEL BANK LOAN AND SECURITY AGREEMENT WEST\291919990.7 This Loan And Security Agreement (“Agreemen
November 4, 2020	8-K/A	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant - 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 29, 2020 SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation or organi
October 29, 2020	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 29, 2020 SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation or organiza
October 29, 2020	EX-9.01	Loan and Security Agreement, dated as of October 29, 2020, by and between Silk Road Medical, Inc. and Stifel Bank. EX-9.01 7 silkroad-8xkexredactedloan.htm EX-9.01 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. SILK ROAD MEDICAL, INC. STIFEL BANK LOAN AND SECURITY AGREEMENT WEST\291919990.7 This Loan And Security Agreement (“Agreemen
October 1, 2020	EX-99.1	Silk Road Medical Names Rick Anderson to Board of Directors Silk Road Medical Names Rick Anderson to Board of Directors SUNNYVALE, Calif. – October 1, 2020 – Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that medical device industry veteran Rick Anderson has joined its board of directors. Anderson brings over 30 years of senior executive leadership experience in the medi
October 1, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 29, 2020 SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation or organi
September 21, 2020	EX-99.1	Silk Road Medical Strengthens Leadership Team Silk Road Medical Strengthens Leadership Team SUNNYVALE, Calif. – September 21, 2020 – Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that it is strengthening its leadership team with two appointments. William Whealon, Ph.D. has joined the company as Executive Vice President of Research and Development, effective
September 21, 2020	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 21, 2020 SILK ROAD MEDI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 21, 2020 SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation or organi
August 13, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q REGISTRATION STATEMENT Under The Securities Act of 1933 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period
August 5, 2020	EX-99.1	Silk Road Medical Reports Second Quarter 2020 Financial Results EX-99.1 2 silkq22020earningspres.htm EX-99.1 Silk Road Medical Reports Second Quarter 2020 Financial Results SUNNYVALE, Calif. – August 5, 2020 – Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended June 30, 2020. “While the second quarter posed several challenges, we are ple
August 5, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 5, 2020 SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation or organizati
July 9, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 8, 2020 SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation or organization
May 28, 2020	DEF 14A	- DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State
May 15, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q REGISTRATION STATEMENT Under The Securities Act of 1933 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period
May 8, 2020	EX-99.1	Silk Road Medical Announces Proposed Public Offering of Common Stock Exhibit 99.1 Silk Road Medical Announces Proposed Public Offering of Common Stock SUNNYVALE, Calif. – May 5, 2020 – Silk Road Medical, Inc. (Nasdaq: SILK) (“Silk Road Medical”), a company focused on reducing the risk of stroke and its devastating impact, announced today the commencement of a proposed underwritten public offering of $100 million of shares of its common stock. $75 million of the sha
May 8, 2020	EX-99.2	Silk Road Medical Announces Pricing of Upsized Public Offering Exhibit 99.2 Silk Road Medical Announces Pricing of Upsized Public Offering SUNNYVALE, Calif. – May 5, 2020 – Silk Road Medical, Inc. (Nasdaq: SILK) (“Silk Road Medical”), a company focused on reducing the risk of stroke and its devastating impact, today announced the pricing of an underwritten public offering of 6,808,154 shares of its common stock at a public offering price of $39.00 per share,
May 8, 2020	SC 13G/A	SILK / Silk Road Medical Inc / WP X Finance, L.P. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1) Silk Road Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 82710M100 (CUSIP Number) May 5, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
May 8, 2020	EX-99.3	Silk Road Medical Announces Closing of Follow-on Public Offering Exhibit 99.3 Silk Road Medical Announces Closing of Follow-on Public Offering SUNNYVALE, Calif. –May 8, 2020– Silk Road Medical, Inc. (Nasdaq: SILK) (“Silk Road Medical”), a company focused on reducing the risk of stroke and its devastating impact, today announced the closing of an underwritten public offering of 6,808,154 shares of its common stock at a public offering price of $39.00 per share.
May 8, 2020	EX-1.1	Underwriting Agreement, dated May 5, 2020, by and among Silk Road Medical, Inc. and J.P. Morgan Securities LLC and BofA Securities, Inc., as representatives of the several underwriters named therein. EX-1.1 2 silkexhibit115820.htm EXHIBIT 1.1 Exhibit 1.1 Execution Version UNDERWRITING AGREEMENT SILK ROAD MEDICAL, INC. 6,808,154 Shares of Common Stock Underwriting Agreement May 5, 2020 J.P. Morgan Securities LLC BofA Securities, Inc. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o BofA Secu
May 8, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 5, 2020 SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation or organization)
May 7, 2020	424B5	CALCULATION OF REGISTRATION FEE Title of Each Class of Securities Offered Amount to be Registered(1) Maximum Offering Price Per Unit Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, $0.001 par value per share 7,829,377 $ 3 Filed Pursuant to Rule 424(b)(5) Registration No. 333-238007 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities Offered Amount to be Registered(1) Maximum Offering Price Per Unit Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, $0.001 par value per share 7,829,377 $ 39.00 $ 305,345,703 $ 39,633.87 (1) Includes 1,021,223 shares of common stock that the und
May 5, 2020	S-3ASR	- S-3ASR S-3ASR 1 silks-3asr.htm S-3ASR As filed with the Securities and Exchange Commission on May 5, 2020 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT Under The Securities Act of 1933 Silk Road Medical, Inc. (Exact name of Registrant as specified in its charter) Delaware 20-8777622 (State or other jurisdiction of incorporati
May 5, 2020	EX-4.2	Form of Indenture Exhibit 4.2 SILK ROAD MEDICAL, INC. [], AS TRUSTEE TO INDENTURE DATED AS OF [●] DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.1 Definitions. 1 Section 1.2 Compliance Certificates and Opinions. 6 Section 1.3 Form of Documents Delivered to Trustee. 7 Section 1.4 Acts of Holders; Record Dates. 7 Section 1.5 Notices, etc., to Trust
May 5, 2020	424B5	Subject to Completion Preliminary Prospectus Supplement dated May 5, 2020 Filed Pursuant to Rule 424(b)(5) Registration No. 333-238007 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to these securities has become effective under the Securities Act of 1933, as amended. This preliminary prospectus supplement and the accompanying prospectus are not an offer to s
April 30, 2020	EX-99.1	Silk Road Medical Reports First Quarter 2020 Financial Results Silk Road Medical Reports First Quarter 2020 Financial Results SUNNYVALE, Calif. – April 30, 2020 – Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended March 31, 2020. “As we continue through these challenging times, we are confident in the foundational strength of our busin
April 30, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 30, 2020 SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation or organizati
April 6, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 6, 2020 SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation or organizatio
April 6, 2020	EX-99.1	Silk Road Medical Provides COVID-19 Pandemic Update Silk Road Medical Provides COVID-19 Pandemic Update SUNNYVALE, Calif. – April 6, 2020 – Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today provided a corporate update in response to the COVID-19 pandemic. Silk Road Medical is committed to working closely with its partners as part of the coordinated public and private sector re
April 2, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 27, 2020 SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation or organizati
March 2, 2020	S-8	SILK / Silk Road Medical Inc S-8 - - S-8 S-8 1 silkroad-formsx8.htm S-8 As filed with the Securities and Exchange Commission on March 2, 2020 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S‑8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 20-8777622 (State or other jurisdiction of incorpora
March 2, 2020	EX-4.5	Description of the registrant’s securities registered pursuant to Section 12 of the Securities Exchange Act of 1934 EX-4.5 2 silk201910-kexhibit45d.htm EX-4.5 Exhibit 4.5 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Silk Road Medical, Inc. (the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, par value $0.001 per share. As used in this summary, the terms
March 2, 2020	10-K	SILK / Silk Road Medical Inc 10-K - Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 . OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38847 SILK ROAD ME
February 26, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 26, 2020 SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation or organiz
February 26, 2020	EX-99.1	Silk Road Medical Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Full Year 2020 Outlook Silk Road Medical Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Full Year 2020 Outlook SUNNYVALE, Calif.
February 7, 2020	SC 13G	SILK / Silk Road Medical Inc / WP X Finance, L.P. - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Silk Road Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 82710M100 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
February 7, 2020	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 d869921dex991.htm EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.001 par value, of Silk Road Medical, Inc. and
February 4, 2020	SC 13G	SILK / Silk Road Medical Inc / Norwest Venture Partners Xiii, Lp - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Silk Road Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 82710M100 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic
February 4, 2020	SC 13G	SILK / Silk Road Medical Inc / WELLS FARGO & COMPANY/MN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) SILK ROAD MEDICAL INC (Name of Issuer) COM (Title of Class of Securities) 82710M100 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is
November 13, 2019	10-Q	SILK / Silk Road Medical Inc 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q REGISTRATION STATEMENT Under The Securities Act of 1933 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition pe
October 29, 2019	EX-99.1	Silk Road Medical Reports Third Quarter 2019 Financial Results Silk Road Medical Reports Third Quarter 2019 Financial Results SUNNYVALE, Calif. – October 29, 2019 – Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended September 30, 2019. “Our third quarter results reflect strong execution across our entire organization,” said Erica Roger
October 29, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 29, 2019 SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation or organiza
August 27, 2019	EX-99.1	Forward Looking Statement Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and Silk Road’s silkinvestorpresentation Forward Looking Statement Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and Silk Road’s own internal estimates and research.
August 27, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 27, 2019 SILK ROAD MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38847 20-8777622 (State or other jurisdiction of incorporation or organizat
August 13, 2019	10-Q	SILK / Silk Road Medical Inc 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q REGISTRATION STATEMENT Under The Securities Act of 1933 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period
August 12, 2019	424B4	Per Share Filed pursuant to Rule 424(b)(4) Registration Nos. 333-233044 and 333-233157 PROSPECTUS 4,200,000 Shares Common Stock This is a public offering of shares of common stock of Silk Road Medical, Inc. The selling stockholders identified in this prospectus are offering 4,200,000 shares of our common stock. We are not selling any shares of common stock under this prospectus, and will not receive any pro
August 9, 2019	S-1MEF	SILK / Silk Road Medical Inc S-1MEF - - S-1MEF As filed with the Securities and Exchange Commission on August 8, 2019 Registration No.
August 6, 2019	EX-10.20	Change in Control and Severance Agreement between the registrant and Andrew Davis, dated as of March 21, 2019 Exhibit 10.20 SILK ROAD MEDICAL, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the “Agreement”) is made between Silk Road Medical, Inc. (the “Company”) and Andrew Davis (the “Executive”), effective as of March 21, 2019 (the “Effective Date”). This Agreement provides certain protections to the Executive in connection with a change in control of the C
August 6, 2019	EX-3.3	Amended and Restated Certificate of Incorporation of the registrant, to be in effect upon the completion of this offering. Exhibit 3.3 SILK ROAD MEDICAL, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Silk Road Medical, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: A. The name of the Corporation is Silk Road Medical, Inc., and the original Certificate of Incorporation of this Corporation was filed with the Secretary of State
August 6, 2019	EX-10.14	Confirmatory Employment Letter between the registrant and Lucas Buchanan, dated as of March 21, 2019 Exhibit 10.14 1213 INNSBRUCK DR., SUNNYVALE, CA 94089 WWW.SILKROADMED.COM March 21, 2019 Lucas Buchanan c/o Silk Road Medical, Inc. 1213 Innsbruck Drive Sunnyvale, CA 94089 Re: Confirmatory Employment Letter Dear Lucas: This letter agreement (the “Agreement”) is entered into between Lucas Buchanan (“you”) and Silk Road Medical, Inc. (the “Company” or “we”), effective as of March 21, 2019 (the “Eff

SILK / Silk Road Medical, Inc - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)